{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hickman RA"],"funding":["National Institute of Neurological Disorders and Stroke","NCATS NIH HHS","NIDDK NIH HHS","National Institute of Diabetes and Digestive and Kidney Diseases","NCI NIH HHS","NINDS NIH HHS"],"pagination":["415-427"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7987644"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["47(3)"],"pubmed_abstract":["Aims
The gonadotroph tumour (GT) is the most frequently resected pituitary neuroendocrine tumour. Although many symptomatic GT are successfully resected, some recur. We sought to identify histological biomarkers that may predict recurrence and explore biological mechanisms that explain this difference in behaviour.Methods
SF-1 immunohistochemistry of 51 GT, a subset belonging to a longitudinal prospective cohort study (n = 25), was reviewed. Four groups were defined: Group 1-recently diagnosed GT (n = 20), Group 2-non-recurrent GT with long-term follow up (n = 11), Group 3-initial resections of GT that recur (n = 7) and Group 4-recurrent GT (n = 13). The percentage of SF-1 immunolabelling in the lowest staining fields (SF-1 labelling index (SLI)) was assessed and RNA sequen"],"journal":["Neuropathology and applied neurobiology"],"pubmed_title":["Gonadotroph tumours with a low SF-1 labelling index are more likely to recur and are associated with enrichment of the PI3K-AKT pathway."],"pmcid":["PMC7987644"],"funding_grant_id":["R01DK110771","UL1 TR000040","R01 NS070600","R01NS070600","UL1 TR001873","P30 CA008748","R01 DK110771"],"pubmed_authors":["Lopes B","Freda PU","Bruce JN","Otten M","Flowers XE","Khandji AG","Siegelin M","Hickman RA","Faust PL"],"additional_accession":[]},"is_claimable":false,"name":"Gonadotroph tumours with a low SF-1 labelling index are more likely to recur and are associated with enrichment of the PI3K-AKT pathway.","description":"Aims
The gonadotroph tumour (GT) is the most frequently resected pituitary neuroendocrine tumour. Although many symptomatic GT are successfully resected, some recur. We sought to identify histological biomarkers that may predict recurrence and explore biological mechanisms that explain this difference in behaviour.Methods
SF-1 immunohistochemistry of 51 GT, a subset belonging to a longitudinal prospective cohort study (n = 25), was reviewed. Four groups were defined: Group 1-recently diagnosed GT (n = 20), Group 2-non-recurrent GT with long-term follow up (n = 11), Group 3-initial resections of GT that recur (n = 7) and Group 4-recurrent GT (n = 13). The percentage of SF-1 immunolabelling in the lowest staining fields (SF-1 labelling index (SLI)) was assessed and RNA sequen","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Apr","modification":"2026-05-02T22:42:17.588Z","creation":"2024-11-15T21:00:52.751Z"},"accession":"S-EPMC7987644","cross_references":{"pubmed":["33128255"],"doi":["10.1111/nan.12675"]}}